REVIEW_FUTURE_ONCOLOGY._IRIS_EU9_Suppl_Tables_TC_v2.0_06.09.21.docx (98.65 kB)
Supplementary Tables – Real-world treatment of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer: the Europe IRIS study
dataset
posted on 2021-11-29, 15:17 authored by Figshare Future Science GroupFigshare Future Science Group, Katie Mycock, Lin Zhan, Kieran Hart, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra|
Supplementary Table S1. Patient inclusion criteria Supplementary Table S2. Therapeutic indications for IBRANCE (palbociclib) in the EU Supplementary Table S3. Patient demographics and clinical characteristics for the nine individual EU countries Supplementary Table S4. Palbociclib treatment patterns for the nine individual EU countries Supplementary Table S5. Response to palbociclib treatment for the nine individual EU countries Real-world treatment of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer: the Europe IRIS study |
